Figure 6
Antitumor activity of TAM and CXB in Swiss albino mice bearing S180 tumors. Mice were intraperitoneally injected with TAM (2 mg/kg body weight), CXB (3.7 mg/kg body weight), or both (2 and 1 mg/kg body weight, respectively) on alternative days after tumor cell implantation and continued for 2 weeks. (A) Mice images bearing S180 tumors with different treated groups at the time of sacrifice, (B) Animal body weight on 7th and 14th day of treatment. Data are means ± SD of three independent experiments. (C) MTT assay of proliferation of splenocytes from mice. Data are means ± SD of three independent experiments. p < 0.05 compared with untreated mice. (D) Cell-cycle phase distribution study of S180 cancer cells isolated from the intraperitoneal region of treated animals exposed to TAM and CXB for 48 h followed by PI staining. (E) Cell-cycle phase distribution analysis of ex vivo grown S180 cells exposed to TAM and CXB for 48 h followed by PI staining. Enzyme activity assays of catalase (F) and superoxide dismutase (G) from liver and kidney tissue homogenates of S180 tumor-bearing Swiss albino mice after drug treatment. Data are means ± SD of three independent experiments. (H) Intracellular ROS accumulation in MCF-7 cells (top) and MDA-MB-231 cells (bottom) treated with TAM, CXB, or both for 24 h was assessed by DCFDA staining and performed flow cytometry. T + C, TAM plus CXB; UT, untreated cells.